Does Molina Healthcare Cover Propecia?

The direct answer

Propecia itself is almost never on a Molina formulary. The reason is not the drug's safety profile, it is the diagnosis. Androgenetic alopecia (pattern hair loss) is treated as a cosmetic condition by most state Medicaid programs, and the Centers for Medicare & Medicaid Services (CMS) does not require states to cover cosmetic treatments as part of the mandatory Medicaid benefit package (cms.gov). Because Molina administers Medicaid managed care under state contracts, its Medicaid formularies generally follow that exclusion. Generic finasteride 1 mg can occasionally be covered, most often on Marketplace (ACA exchange) plans where the state's essential health benefits benchmark includes a broader dermatology drug list, but this is plan-specific and not something a general article can confirm for your policy. Finasteride 5 mg, prescribed for BPH, is a different story: it is a recognized medical (non-cosmetic) indication and is commonly placed on a low generic tier.

If you need a single sentence you can act on: check your own Molina plan's current formulary and prior-authorization policy before assuming either way, because the cosmetic-versus-medical distinction, not the drug's safety, is what usually decides coverage.

Propecia and finasteride: what they are

Finasteride is a synthetic 5-alpha reductase type II inhibitor. It reduces conversion of testosterone to dihydrotestosterone (DHT), the hormone implicated in the miniaturization of genetically susceptible hair follicles. The FDA approved finasteride 1 mg, marketed under the brand name Propecia, in 1997 specifically for male pattern hair loss (Drugs@FDA, NDA 020788). A separate, higher-dose formulation of the same molecule, 5 mg, is FDA-approved for benign prostatic hyperplasia and has historically been marketed as Proscar. These are the same active ingredient at different doses and for different approved indications, which is exactly why insurers treat them differently.

Generic finasteride 1 mg is bioequivalent to brand Propecia and is dramatically less expensive at retail. Even on the rare plan that covers finasteride for hair loss, mandatory generic-substitution rules mean the brand product is essentially never dispensed in place of the generic.

Why Medicaid plans usually exclude it

Medicaid's mandatory benefit categories, defined by CMS, do not include cosmetic drugs. States decide, through their preferred drug lists (PDLs), which optional drugs to add back in, and finasteride 1 mg for alopecia is rarely one of them. Molina's Medicaid formularies are built around each state's PDL, so Molina has limited ability to cover a drug that the state itself has excluded, even when a prescriber believes it is clinically appropriate.

This is different from Molina's Marketplace business. Marketplace plans sold through healthcare.gov or a state exchange must cover the ten essential health benefit categories, including prescription drugs, based on the state's benchmark plan. Whether that benchmark plan's formulary includes finasteride 1 mg for alopecia varies by state and by plan year, which is why two Molina members in different states, or even different plan types in the same state, can get different answers to the same question.

Molina Medicare products, where offered, follow Medicare Part D rules. Part D specifically excludes drugs used for cosmetic purposes or hair growth under Section 1860D-2(e)(2)(A) of the Social Security Act, so finasteride 1 mg for alopecia is typically not a Part D benefit even though finasteride 5 mg for BPH is.

What the trial evidence actually supports

Randomized trials of finasteride 1 mg in men with androgenetic alopecia have reported meaningful improvements in hair count and patient- and investigator-rated hair growth compared with placebo over periods of one to two years, with benefits that plateau or reverse if the drug is stopped. The commonly cited large multi-center trial supporting the original FDA approval is frequently referenced in dermatology literature, but the specific percentage figures attached to it vary between secondary sources, and any precise number should be checked against the original published trial or the FDA label before it is used in a clinical or coverage argument. The known, reversible side effects reported in trials include decreased libido, erectile dysfunction, and reduced ejaculate volume in a minority of men; these typically resolved after discontinuation in trial follow-up, though individual experience varies.

Evidence on female pattern hair loss and on off-label agents (spironolactone, low-dose oral minoxidil, dutasteride) exists in smaller trials and systematic reviews, but the specific effect sizes reported in various secondary summaries should not be treated as settled without checking the primary publication. Where this article previously cited exact percentages for those studies, those numbers require verification and are not repeated here as precise facts.

Prior authorization: what is a real federal rule and what is plan-specific

Federal Medicaid managed care regulation (42 CFR 438.210) requires plans like Molina to decide standard prior authorization requests within a defined timeframe and expedited requests faster for urgent clinical need (cms.gov). That timing requirement is a real regulatory floor. What is not a fixed fact is how a hair-loss request gets classified (almost always non-urgent), how long the full cycle takes once requests for additional documentation are included, or what specific clinical documentation will succeed. Those depend on the state, the plan, and the individual case, and a prescriber's office or Molina member services is the only accurate source for a current answer.

A prior authorization request for finasteride typically needs a diagnosis code, the prescribed drug and dose, and a clinical rationale. Documentation of functional or psychological impact, or an underlying non-cosmetic diagnosis (for example, alopecia secondary to a documented autoimmune or hormonal condition rather than androgenetic alopecia alone), is sometimes used to support medical-necessity arguments. Success is not guaranteed and depends on state-specific review criteria.

If a request is denied, Molina members generally have the right to an internal appeal reviewed by a medical director. Medicaid members who are denied again can request a state fair hearing; Marketplace members can request an external review through an independent review organization. These appeal rights come from Medicaid and ACA regulatory structure rather than from Molina's discretion, but the exact forms and deadlines are plan- and state-specific and should be confirmed with your plan's denial letter, which is required to include appeal instructions.

Verification checklist: what is stable versus what changes

Use this before relying on any coverage claim about Propecia or finasteride, from this article or any other source.

Stable facts you can generally rely on without re-checking often:

• Finasteride 1 mg (Propecia) is FDA-approved for male androgenetic alopecia; finasteride 5 mg is FDA-approved for BPH. These are distinct approved indications for the same molecule.
• Medicaid's mandatory federal benefit package does not require coverage of cosmetic treatments; states decide optional coverage through their preferred drug lists.
• Medicare Part D statutorily excludes drugs used for cosmetic hair growth (Social Security Act §1860D-2(e)(2)(A)).
• Federal Medicaid managed care rules require plans to issue prior authorization decisions within defined standard and expedited timeframes (42 CFR 438.210).
• Denial letters from Molina are required to include appeal and, where applicable, state fair hearing or external review instructions.

Date-sensitive facts that must be re-verified before you act, and where to check them:

• Whether your specific Molina plan (Medicaid, Marketplace, or Medicare) currently lists finasteride 1 mg for alopecia, check the plan's online formulary tool or call member services using the number on your ID card.
• Which tier finasteride 1 mg or 5 mg sits on, and your copay, same source, and formularies are typically updated on a quarterly cycle.
• Actual prior-authorization processing time for your case, ask the prescriber's office or Molina directly; published regulatory timeframes are minimums for a decision, not guarantees of total elapsed time including documentation requests.
• Cash prices at GoodRx, Cost Plus Drugs, or local pharmacies, these change frequently and should be checked at the time of fill, not assumed from an older figure.
• Whether a manufacturer patient assistance program exists for brand Propecia, check the manufacturer's current program page directly, since brand ownership and program availability can change.
• State-specific Medicaid PDL inclusion or exclusion of finasteride, this varies by state and is revised periodically; do not assume one state's answer applies to another.

What Molina is more likely to cover instead

Topical minoxidil is available over the counter without a prescription, so insurance coverage is not a relevant barrier; a systematic review from the Cochrane Collaboration has evaluated minoxidil for female pattern hair loss and found evidence supporting its effectiveness for regrowth, though exact comparative figures between concentrations should be checked in the review itself before being quoted precisely.

Spironolactone, prescribed off-label for female pattern hair loss, is commonly covered by Molina under its on-label indications (hypertension, heart failure, hyperaldosteronism) as a low-tier generic; coverage for the off-label hair-loss use itself is not guaranteed and depends on how the prescription is coded.

Low-dose oral minoxidil, prescribed off-label for hair loss, is sometimes covered when billed under an on-label indication such as hypertension. Dutasteride, a dual 5-alpha reductase inhibitor used off-label for androgenetic alopecia, may be covered under its FDA-approved BPH indication rather than for hair loss specifically. In each case, the coverage pathway runs through the on-label diagnosis, not the hair-loss use, which is worth discussing with a prescriber if finasteride is denied.

Platelet-rich plasma (PRP) injections have been studied for androgenetic alopecia in small randomized trials, but PRP is a self-pay cosmetic procedure not covered by Molina or most other insurers, and per-session cost varies by clinic and geography rather than following a fixed national price.

Evidence boundaries

Established: finasteride 1 mg is FDA-approved for male androgenetic alopecia and has trial evidence of benefit over placebo in men over one to two years of treatment; the cosmetic classification of alopecia, not drug safety, is the primary reason Medicaid plans exclude it; federal rules set minimum PA response timeframes and appeal rights.

Plausible but plan-dependent, not a general fact: whether your specific Molina Marketplace, Medicaid, or Medicare plan covers finasteride 1 mg, what tier it sits on, and whether a given prior-authorization argument (psychological distress, alternate diagnosis code) will succeed.

Not established from the material available for this article: precise percentage effect sizes for finasteride, dutasteride, spironolactone, or oral minoxidil trials, exact current cash prices at specific discount pharmacies, and state-by-state lists of which Medicaid programs do or do not cover finasteride 1 mg. These require checking the primary trial publication or your plan's current documents directly rather than relying on a secondary summary.